Weekly neuro beat. The reach product.
NeuroPulse Wk 42: Arrowhead Cut Tau by 73% With a Shot Under the Skin Athithi Verma·19 October 2026·11 min read·Synopulse NeuroPulseDeep pine banner. A violet neural network of neurons and synapses fills the right side, with a gold signal pulse firing along a chain of neurons, beside the NeuroPulse wordmark under the Synopulse and The … Read more
The intramuscular olanzapine depot needs three hours of monitoring after every injection. Teva’s monthly version needs none.
Tavapadon now has a benchmark, a royalty valuation and an approval, in that order. AbbVie still has not named a price.
Otsuka opened early access for ulefnersen the day before the topline. A sponsor that prepares supply first expected to win.
The NDA and the enrolment pause went out in one release. Xenon says the events match the mechanism, not the indication.
Jazz committed $820 million at signing for an epilepsy drug with one early trial behind it. The justification is a regulatory pathway, not the data.
FDA approved the first medicine treating narcolepsy type 1 as a disease rather than a symptom set. Takeda cannot sell it for up to ninety days.
FDA told NeuroPace its generalized epilepsy expansion is not approvable as filed. An open-label 77% cannot rescue a randomized endpoint that missed.
Lundbeck’s Fast Track makes three orexin programmes in two weeks. Plus a Duchenne filing with a January date, and a CHMP slip caused by a contract manufacturer.
The Alzheimer’s Association International Conference drove the week’s pipeline news, but the signal that mattered most came from a lab: the first brain link that let one paralysed person move and feel through another. Around it, a tau target validated and contested in the same week, an oral entrant scaling in Huntington’s, and anti-amyloid therapy fighting its real battle, which is access.